Introduction
Epileptic seizures are one of the most frequent presenting symptoms of gliomas, particularly in low-grade gliomas. Approximately 80% 1 of glioma patients will experience at least one seizure during the course of the disease, and the aetiology of gliomarelated seizure is most likely multifactorial and complex, thereby remaining poorly understood. The risk of seizure development is strongly associated with the histological types and WHO scales of gliomas. 2 Many studies have indicated that low-grade gliomas, which grow slowly and invade normal surrounding brain tissue, are most likely to cause epilepsy. [2] [3] [4] The mechanisms by which high-grade gliomas may cause epilepsy are probably different, involving more significant tissue damage, such as necrosis or hemosiderin deposition. 2 Tumour localisation 3 is another factor strongly affecting seizure risk. Patients with glioma in the temporal, insular or frontal lobes have a higher risk of developing epileptic seizures preoperatively than patients with occipital and deep-seated lesions. Interestingly, based on a study of 332 lowgrade glioma patients, Chang et al. 4 observed that seizure recurrence was associated with tumour progression and that the over-expression of certain biomarkers (P53, Ki-67, MMP-9 and MGMT) might be correlated with poor survival in patients with gliomas. Therefore, it is possible that there might be a relationship between these different genetic factors and postoperative seizure outcomes. 5 However, to date, biomarkers that predict pre-or postoperative epileptic seizures have not been identified. Ki-67 6 is an excellent marker to determine the growth fraction of a given cell population, and the expression of ki-67 is a routine test performed in many neurosurgery centres to predict the level of malignancy of gliomas and the prognosis of patients. The aim of this retrospective study was to investigate whether the overexpression of ki-67 (!10%) in diffusely infiltrating glioma is associated with poor postoperative seizure control. We excluded Purpose: Seizures are the most common initial symptom in patients with low-grade gliomas, and approximately 30% of these patients still suffer from epilepsy after gross-total resection of the tumour. We examined the relationship between the overexpression of ki-67 in WHO grade II gliomas and seizure control.
Methods: A series of 93 histologically confirmed WHO grade II glioma tissues were analysed through immunohistochemical staining for ki-67 expression. Follow-up visits regarding seizure control were scheduled at 12 months. The Engel classification was used to categorise patients' seizure status. Results: Of the 93 patients analysed, 65 (66.3%) patients initially presented with seizures. A total of 36 patients were diagnosed with WHO grade II oligodendrogliomas, 29 patients had oligoastrocytomas and 28 patients had astrocytomas. Ki-67 was over-expressed in 15 patients. One year after surgery poor seizure control was observed in 11 of these patients. In contrast, low ki-67 expression (<10%) was found in 78 patients. Poor seizure control was observed in 36 patients (difference between ki-67 over-and low expression groups P = 0.002). Logistic regression analysis revealed that patients with gross-total resection achieved better seizure control while ki-67 overexpression and age below 38 years were poor seizure control factors explained of the variance of seizure outcome (OR: 0.382, 4.354 and 1.822, respectively).
Conclusions:
In WHO grade II gliomas, Ki-67 is a molecular marker which predicts poor seizure control of glioma patients after the resection of the tumour. Gross-total resection, ki-67 overexpression and age below 38 years significantly affect seizure prognosis. ß 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
high-grade gliomas (WHOIII/IV) from this analysis due to the high frequency of ki-67 overexpression and low frequency of epileptic seizures. In addition, the treatment strategies for low-and highgrade gliomas are different, which might contribute to differences in the prognosis of the patients, including seizure outcomes. We also excluded WHO grade I gliomas because the morbidity of these tumours was much lower compared with other tumour types, and many of the patients preferred non-operative treatments (Fig. 1 ).
Materials and methods

Patients
Patients at the Glioma Treatment Centre, West China Hospital, Chengdu, China with newly diagnosed and histologically confirmed WHO grade II gliomas between January 2011 and January 2012 were included. The ethic committee of the hospital approved the study, and informed consent was obtained from all patients. Patients who met the following criteria were enrolled in this research:
(1) 17 years of age or older, (2) histopathologically confirmed diagnosis of WHO grade II glioma, (3) available documentation of first tumour symptoms, (4) MRI confirmation of invasion of cortex or subcortical white matter and (5) gliomas only in the occipital lobe (6) availability of either fresh, frozen tumour or paraffin-embedded tumour tissue. In total, 93 patients were included.
Clinical categorisation and follow-up
An independent neurologist (Liu Shuang), who was not involved the treatment of the patients and blinded to the results of ki-67 expression, identified patients' initial symptoms. The initial symptoms were categorised into generalised seizures, partial seizures and non-seizure symptoms. Epilepsy subtypes were classified according to the International League against Epilepsy (ILAE 2001). The patients were followed up by telephone or in the outpatient clinic at 12th months after the tumour resection, and the Engel classification was used to categorise seizure outcome after surgery. For the outcome analyses, Engel classification was dichotomised as class I (completely seizure free) versus classes II-IV (not seizure free).
Histopathology and the expression of ki-67
At least two experienced neuropathologists re-defined all of the histological tissues according to the 2007 WHO classification of brain tumours. If the two neuropathologists did not agree on the definition of the pathological type, a third neuropathologist reevaluated the tumour tissue and provided a definitive opinion. Immunohistochemical staining for ki-67 was performed on formalin-fixed, paraffin-embedded tissue sections following the manufacturer's standard protocol (mouse monoclonal antibody-MIB-1, Maxim, USA). Two independent observers individually reviewed and scored each slide stained for Ki-67.
MRI characteristics
MRI scans were re-examined. Tumours were considered to be infiltrating the frontal, parietal, temporal lobes and insula when there was infiltration extending more than 1 cm into the cortex or subcortical white matter on FLAIR or T2 images. If tumours affected multiple lobes, infiltration of each lobe was counted (Fig. 2) .
Statistical analysis
All statistical analyses were performed using SPSS version 17.0, and for all analyses, a type I error of a = 5% was defined. Univariate analyses were performed using the chi-square test for dichotomous variables and the Mann-Whitney U-test for continuous nonparametric data.
Results
A total of 93 patients with newly diagnosed and histologically confirmed WHO grade II gliomas were included in the analysis. Of these patients, 36 were diagnosed with WHO grade II oligodendrogliomas, 29 patients had oligoastrocytomas and 28 astrocytomas. There were 53 (55.5%) males and 40 (45.5%) females; the median age at initial resection of the glioma was 48.7 years. Tumours involved the frontal lobe in 45 cases, the temporal lobe in 41 cases, the parietal lobe in 14 cases and the insular lobe in 8 cases.
Patients with and without seizures as the initial symptom did not differ in terms of median age at presentation (48.6 vs. 48.9 years, respectively; P = 0.8772, F test). The most common type of preoperative seizure types were secondary generalised (41.5%) followed by simple partial (30.7%), complex partial (23.8%) and a combination of partial and generalised seizures (4%).
The majority of patients (69.8%) were completely seizure free (Engel class I) at 12 months after glioma surgery, the remaining patients were not seizure free (Engel classes II-IV). Without special guidelines for postoperative prevention or the treatment of glioma-related epilepsy, antiepileptic drugs (AEDs) were used according to the preference and experience of the doctors. The most commonly used AED was valproic acid (>95%), followed by levetiracetam and carbamazepine. Eleven patients were treated with temozolomide according to the standard 5-day schedule every 28 days (150 mg per square metre for the first cycle, 200 mg per square metre beginning with the second cycle) and 85 patients received radiotherapy according to National Comprehensive Cancer Network (NCCN) Guidelines for Central Nervous System Cancers ( Table 1) .
Ki-67 was over-expressed in 15 glioma tissues, including 3 astrocytoma, 6 oligodendroglioma and 6 oligoastrocytoma samples. A total of 11 of these 15 patients experienced poor seizure control at 12 months follow-up. Oligodendrogliomas and oligoastrocytomas showed ki-67 overexpression compared with astrocytomas. Seizures more frequently occurred in tumours infiltrating the temporal lobe (34/41, 82.9%), followed by the frontal lobe (33/ 45, 75.0%), insula (5/8, 62.5%), and parietal lobe (8/14, 57.1%) (Tables 2-4).
Discussion
Over 80% of glioma patients will experience at least one seizure during the course of their disease, and approximately one-third of these patients will develop seizures, which are refractory to traditional anti-epileptic drugs, even after gross-total tumour resection. 7 Uncontrolled seizures have adverse effects on the quality of life of glioma patients, particularly of those who have Thirty-six patients (38.7%) of our series were found to have oligodendrogliomas, a slightly higher proportion than in the study by You et al. 1 and van Breemen et al. 9 Given that oligodendrogliomas and oligoastrocytomas are more likely to exhibit Ki-67 over-expression than astrocytomas, this could explain our findings and histological subgroup analyses should be performed in future studies. Many studies 8, [10] [11] [12] have demonstrated that the tumour localisation influences the likelihood of epileptic activity. Occipital lobe neoplasms are least likely to cause tumour-related epilepsy; thus, we excluded occipital gliomas from the present study. Liigant and coworkers 13 showed that the seizure activity is rarely observed in infratentorial and sellar tumours, unless these lesions infiltrate the cerebral cortex, so these tumours were also excluded from our series. In the present study, we observed that seizures primarily occurred in glioma-infiltrated temporal lobe, consistent with the results of previous studies. 11, 12 Interestingly, no insular gliomas, showing ki-67 overexpression were observed, potentially reflecting the sample small size. Moreover, insular glioma-related seizures could represent a unique seizure subtype with its own pathogenesis and genetic characteristics. 8 The level of expression of ki-67 was not related to the preoperative seizure occurrence risk. However, we observed that gross-total resection, ki-67 overexpression and age below 38 years significantly impacted the seizure prognosis. At follow up 12 months after resection approximately 91.3% of the 93 glioma patients showed no tumour progression, 8 patients had tumour progression and 1 patient had died. We also observed that tumour progression was typically accompanied by seizure recurrence, consistent with the results of Chang EF 4 , who performed a follow up study of 332 low-grade glioma patients. Interestingly, in that study young age was associated with relatively poor seizure control, suggesting that elderly patients are more likely to present with high-grade gliomas associated with a lower risk of inducing seizures.
The role of ki-67 in glioma-related epilepsy remains unknown, whereas the development of epilepsy through tumoural or peritumoural changes in glioma patients has been demonstrated in many previous studies. 14, 15 Peritumoural amino acid 16 and receptor changes 17 have been observed in rat epilepsy models rats or the brain tissues from glioma patients, and many studies have suggested that this protein could be a target for the treatment of glioma-related epilepsy. Buckingham et al. 18 showed that glutamate release from primary brain tumours induces epileptic activity, and the inhibition of the Xc À system through sulphasalazine eliminates epileptiform activity. Sontheimer 19 proposed that the invasion of gliomas into the peritumoural zone is partially mediated through chloride (Cl À ) channels that facilitate rapid cell deformation to traverse the confined extracellular space, suggesting that glioma cells induce excitotoxic neuronal cell death through the release of high levels of glutamate, thereby facilitating invasion. Tumoural or peritumoural changes play important roles in the induction of epileptiform activity, 20 and Ki-67 is most likely a cellular marker for proliferation, strictly associated with cell proliferation in human cells. Thus, we propose that the proliferation of the tumour cells plays a vital role in seizure control. When high levels of ki-67 expression are observed in tumour tissue, residual tumour tissue may influence the peritumoural microenvironment even after gross-total resection, explaining why glioma patients with strong ki-67 expression have a poor seizure prognosis. Unfortunately, there are no treatment guidelines for gliomarelated epilepsy, although the unique pathogenesis of this condition is different from any other type of epilepsy. In this study, AEDs were used according to the custom of the hospital or the preference of the doctor. However, the use of ADEs in patients without a history of epilepsy before surgery to prevent epileptic activity remains under debate. Meta-analysis 21 shows that for patients who do not present with seizures preoperatively, AEDs have no significant preventative effect postoperatively. In the present study, ADEs were stopped within two weeks after surgery in the patients without seizures as the initial symptom; however, this subgroup was classified according to ki-67 status rather than seizure history before surgery, and no significant differences were observed in our analysis. Because of the limited sample size, we could not perform additional analyses taking account of AED use. Based on the findings of our study the use of AEDs as preventative postoperative treatment for glioma-associated seizures could be tested in a prospective randomised controlled trial in patients with ki-67 expression >10%.
In the present study, we observed a correlation between ki-67 expression and clinical symptoms. However, this study has some limitations. A 12-month follow-up period is relatively short for patients with WHO grade II gliomas, and our findings should be confirmed with a longer follow-up period. Furthermore, because of the limited budget, our patient cohort was too small for further subgroup analysis; thus, more patients should be included in future studies. The most commonly used AED at our centre is Valproic acid, an old generation ADE, thus the new AED, levetiracetam, should be used upon patient request or when the seizures are uncontrolled through treatment with only Valproic acid. Finally, the association we have found does not tell us anything about causality. Future experimental studies looking at the relationship of ki-67 expression and seizures will be needed to explore whether there is a direct causal link.
Conclusions
The results of the present study suggest a new role for ki-67 in WHO grade II gliomas. These data suggest that ki-67 overexpression is a predictor or poor postoperative seizure control in patients with WHO grade II gliomas. Gross-total resection, ki-67 overexpression and age below 38 years significantly impacted seizure prognosis in this study. The postoperative use of preventative AEDs may be considered in glioma patients exhibiting ki-67 overexpression, even without a history of epilepsy.
